Spots Global Cancer Trial Database for margetuximab
Every month we try and update this database with for margetuximab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | NCT04262804 | Breast Cancer M... | Margetuximab Trastuzumab Chosen Chemothe... Chosen Chemothe... Chosen Chemothe... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | NCT04262804 | Breast Cancer M... | Margetuximab Trastuzumab Chosen Chemothe... Chosen Chemothe... Chosen Chemothe... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer | NCT04082364 | Gastric Cancer Gastroesophagea... HER2-positive G... | margetuximab Retifanlimab Tebotelimab Trastuzumab Chemotherapy | 18 Years - | MacroGenics | |
| Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer | NCT05227131 | Metastatic Brea... Advanced Breast... HER2-positive B... | Margetuximab Tucatinib Capecitabine | 18 Years - 100 Years | MedSIR | |
| Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer | NCT02492711 | HER-2 Positive ... Metastatic Neop... | Margetuximab Trastuzumab Physician's cho... | 18 Years - | MacroGenics | |
| A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | NCT03219268 | Advanced Solid ... Hematologic Neo... Ovarian Cancer HER2-positive A... Non Small Cell ... Small-cell Lung... Squamous Cell C... Cholangiocarcin... Cervical Cancer TNBC - Triple-N... | tebotelimab 1 m... tebotelimab 3 m... tebotelimab 10 ... tebotelimab 30 ... tebotelimab 120... tebotelimab 300... tebotelimab 400... tebotelimab 600... tebotelimab 800... tebotelimab 120... margetuximab | 18 Years - | MacroGenics | |
| A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC | NCT04398108 | HER2 Positive M... | Margetuximab Ma... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | NCT04262804 | Breast Cancer M... | Margetuximab Trastuzumab Chosen Chemothe... Chosen Chemothe... Chosen Chemothe... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| Margetuximab Expanded Access Program | NCT03133988 | HER2-positive B... HER2-positive C... | Margetuximab | - | MacroGenics | |
| Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer | NCT01828021 | Breast Cancer | Margetuximab | 18 Years - | MacroGenics | |
| Safety Study of MGAH22 in HER2-positive Carcinomas | NCT01148849 | Breast Cancer Gastric Cancer | margetuximab | 18 Years - | MacroGenics | |
| Safety Study of MGAH22 in HER2-positive Carcinomas | NCT01148849 | Breast Cancer Gastric Cancer | margetuximab | 18 Years - | MacroGenics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
